No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.
www.drreddys.comNo one on the platform currently holds DRREDDY.NS.
No tracked institution reports a position in DRREDDY.NS as of their last filing.
No one on the platform has traded DRREDDY.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.0% | 13.7% | 10.9% | — | — | — |
| Rev. Growth % | 3.2% | 12.1% | ||||
| Profit Margin % | 12.8% | 15.9% | 12.7% | |||
| Free Cash Flow Margin % | 9.1% | 8.4% | 7.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $350.9B | +2.2% | $42.99 | $32.32–$55.21 | — | 33 |
| 2028 | $392.1B | +11.7% | $56.52 | $43.95–$76.07 | — | 33 |
| 2029 | $431.8B | +10.1% | $68.98 | $64.81–$76.97 | — | 15 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-21 | $8.83 | $5.33 | -39.6% |
| 2026-05-11 | $11.06 | $2.64 | -76.1% |
| 2026-01-20 | $13.76 | $14.52 | +5.5% |
| 2025-10-24 | $16.81 | $17.22 | +2.4% |
| 2025-07-23 | $18.38 | $17.04 | -7.3% |
| 2025-05-09 | $18.16 | $19.09 | +5.1% |
| 2025-01-23 | $17.91 | $16.94 | -5.4% |
| 2024-11-05 | $16.98 | $15.05 | -11.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| DRREDDY.NSDr. Reddy's Laboratories Limited | $1165.50 | +1.97% | $970.9B | — |
| ALKEM.NSAlkem Laboratories Limited | $5089.50 | -0.94% | $608.5B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1675.45 | +0.39% | $963.7B | — |
| AUROPHARMA.NSAurobindo Pharma Limited | $1679.80 | +0.68% | $966.5B | — |
| CIPLA.NSCipla Limited |
| $1366.00 |
| -0.53% |
| $1.10T |
| — |
| LUPIN.BOLupin Limited | $2096.00 | +1.01% | $955.8B | — |
| LUPIN.NSLupin Limited | $2095.00 | +0.83% | $957.9B | — |
Source: Financial Modeling Prep · peers by sector/industry